Posted On: Wednesday, December 17th, 2014
New and Noteworthy Harvoni cures 98% of Hep C and HIV co-infected participants with genotype 1 virus 98% of Hep C and HIV co-infected participants with genotype 1 virus who took Harvoni (ledipasvir + sofosbuvir) during a 12-week clinical trial were cured, reported researchers at the American Association for the Study of Liver Diseases (AASLD)… Read more »
Posted On: Wednesday, December 10th, 2014
Before reading this newsletter, HepCBC is asking for you and your friends to help make hepatitis C drugs more accessible and affordable. You can do so by answering a few simple questions to help HepCBC make a great Patient group Input submission to CADTH (Canadian Agency for Drugs and Technologies in Health) about the value… Read more »
Posted On: Wednesday, December 3rd, 2014
New and Noteworthy Harvoni (ledipasvir + sofosbuvir) approved by Health Canada In October, Health Canada approved the hepatitis C medication Harvoni (ledipasvir + sofosbuvir) for people over the age of 18 with genotype 1 hepatitis C virus. In clinical trials, the cure rate for this combination was 94% to 100%. Ledipasvir and sofosbuvir are both… Read more »
Posted On: Thursday, November 27th, 2014
The PHCN’s Hepatitis C Treatment Information Project was recently updated. New sections and pages were added to accommodate the ever growing wealth of information that the project now includes. For example, check out the newly rearranged Hep C Drug Pipeline page, which summarizes the treatments that are currently making their way through the hep C… Read more »
Posted On: Wednesday, November 19th, 2014
Posted On: Thursday, November 13th, 2014
Survey participants with hep C or living with/caring for someone with hep C needed immediately! Take this survey! The Canadian Agency for Drugs and Technologies in Health (CADTH) is currently seeking patient group input reports for ombitasvir / paritaprevir / ritonavir and dasabuvir, developed by AbbVie. Thus, Pacific Hepatitis C Network (PHCN) needs your help… Read more »
Posted On: Thursday, November 6th, 2014
New and Noteworthy Interactions with transplant drugs added to simeprevir product monograph The U.S. Food and Drug Administration (FDA) recently approved revisions to the product label information for the direct-acting anti-viral medication simeprevir, known by the brand name Galexos in Canada. The revisions highlighted drug interactions with cyclosporine and tacrolimus, which are used to prevent… Read more »
Posted On: Saturday, October 11th, 2014
Posted On: Saturday, October 11th, 2014
New and Noteworthy CATIE-News: A hepatitis C outbreak among HIV-negative gay men in London, England Some HIV-negative gay men may be at risk for getting hepatitis C. Researchers from London, England found 44 cases of acute Hep C infection in HIV-negative gay men between 2010 and 2014. Among HIV-positive gay men, hepatitis C has been… Read more »
Posted On: Friday, October 3rd, 2014
Take this survey It is 36, mostly multiple choice, questions that are divided into 5 sections. Sections that don’t pertain to you can be easily skipped. The survey’s 5 sections ask about: The impact of hep C on your life (8 questions) Your experience with current hep C treatments (9 questions) The impact on caregivers… Read more »
Posted On: Friday, September 26th, 2014
Posted On: Wednesday, September 17th, 2014
New and Noteworthy Expanded harm reduction services decreased new Hep C infections in Scotland Implementing comprehensive harm reduction services averted an estimated 1400 new Hep C infections in Scotland, reported researchers in PLOS ONE. In 2008, the Scottish government expanded access to sterile injecting equipment, including needles, syringes, cookers, filters and water, and improved access… Read more »
